News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Aims to achieve CDMO sales of US$ 400 million by 2028
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Total investment incurred for setting up the new R&D Rs 250 crore
Expect the international business including CDMO business to pick-up in the second half of the financial year
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Subscribe To Our Newsletter & Stay Updated
